Meet an Unreasonable Venture
Debut Biotechnology
Creating peak-performing products that are rooted in science and clinical testing with impeccable sustainability credentials
Debut Biotech uses advanced biotechnology to discover and produce high-performance, clinically backed ingredients for beauty, food, and nutrition. Its process combines AI-driven ingredient discovery with a capital-light, vertically integrated model to deliver novel, higher performing ingredients in formulation faster than traditional methods. With early commercial traction and an expanding customer pipeline, Debut is building a differentiated portfolio of bioactives to transform consumer product categories through performance-driven innovation.
Notable Achievements
- Named one of the TIME100 Most Innovative Companies of 2025.
- Raised $80M in venture capital and private equity.
- Has seen revenue 100-300% YOY for 3 years.
Currently Operating in 77 Regions
Press Mentions
May 27, 2026
Debut and Natura Partner to Commercialize AI-Discovered Skin Longevity Ingredient for Latin America
Debut Biotechnology has partnered with Natura to commercialize an AI-discovered skin longevity ingredient in Latin America. This collaboration highlights Debut's innovative approach in the...
Read more »More Ventures in Health
Get the Unreasonable Newsletter
Get monthly updates on Debut Biotechnology and all of the other ventures working to solve global challenges.